Yasuhide Yodo

Statistics

Publications

Citations

155

H-Index

Active since

2017

Affiliations

Sumitomo Dainippon Pharma (Japan)(Current)

National Cancer Center Hospital East

Yasuhide Yodo is an author at Sumitomo Dainippon Pharma (Japan) specializing in medicine, dose-limiting toxicity assessment, and pharmacokinetics of anticancer agents.

Publications per year

2017–2020

Publications

Restricted mean survival time as a summary measure of time‐to‐event outcome

Takahiro Hasegawa, Saori Misawa, Shintaro Nakagawa et al. · Pharmaceutical Statistics · 2020 · 51 citations

Public Health, Biostatistics, Clinical Epidemiology +16

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando et al. · Cancer Chemotherapy and Pharmacology · 2020 · 45 citations · Full text

Medicine, Oncology, Pharmacology +16

Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus

Masato Odawara, Ryuzo Kawamori, Naoko Tajima et al. · Diabetology International · 2017 · 29 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +12

A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer

Kohei Shitara, Yasuhide Yodo, Shuichi Iino · In Vivo · 2019 · 18 citations · Full text

Medicine, Oncology, Pharmacology +15

Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan

Nobuo Matsuura, Shin Amemiya, Shigetaka Sugihara et al. · Diabetology International · 2018 · 12 citations · Full text

Medicine, Endocrinology, Pediatrics +14

1–5 of 5